Establishing Medical Fitness is the First Step in Treating Patients with Advanced Ovarian CancerAugust 26th 2019
Before considering intraperitoneal chemotherapy, or dose-dense chemotherapy, for newly diagnosed patients with advanced ovarian cancer, it's not vital to first determine whether the patient is medically fit for these treatments.
The Treatment Landscape for Recurrent Ovarian Cancer Is EvolvingAugust 25th 2019
Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.
Expert Talks Major Advances in the Blood Cancer SpaceJuly 8th 2019
Now that the CD19-targeted CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) have shown durable responses in the relapsed/refractory settings of non-Hodgkin lymphoma, researchers are hopeful that earlier exposure may heighten the curative potential of the modality, explained Mazyar Shadman, MD, MPH.
New Therapies Are Coming for Lung Cancer With Rare MutationsMay 28th 2019
In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.
MONALEESA-3 Data Highlight Ribociclib as Standard in HR+ Breast CancerSeptember 24th 2018
Findings from the MONALEESA-3 trial dispelled the theory that a CDK4/6 inhibitor had to be reserved following recurrence on hormone therapy in postmenopausal patients with hormone receptor (HR)-positive, HER2-negative breast cancer, explained Dennis J. Slamon, MD, PhD.
Multidisciplinary Approach to Adverse Event Management Imperative in GU CancersSeptember 18th 2018
While revisions to guidelines have given clinicians a better handle on how to manage immune-related adverse events (AEs), they have not eliminated the need for individualized treatment of patients with genitourinary (GU) cancers, says Xiao X. Wei, MD, MAS.
HR+ Breast Cancer Treatments Evolving RapidlyAugust 15th 2018
Over the last few years, treatments for patients with metastatic hormone receptor (HR)-positive breast cancer have evolved rapidly. As changes in care continue to progress, nurses need to understand these treatment options, and where the research may take the field in the future.
Maintenance PARP Inhibitors for Ovarian Cancer Make Meaningful Impact on PFSMay 12th 2018
With the approval of rucaparib in April 2018, there are now 3 PARP inhibitors approved for use in the maintenance setting for patients with ovarian cancer who are in a complete or partial response to platinum-based chemotherapy, and they are significantly improving progression-free survival.
NCCN Guidelines on Breast Cancer Impact Clinical Applications of Radiation TherapyApril 20th 2018
The National Comprehensive Cancer Network (NCCN) guidelines on breast cancer now allow physicians to pinpoint the women who are most likely to benefit from post-mastectomy radiation using the latest targeted testing techniques.